zsp1601

ZSP1601 is a novel, first-in-class pan-phosphodiesterase (PDE) inhibitor developed primarily for the treatment of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). It is a small-molecule drug that acts as a nonselective PDE inhibitor with highest affinity for type 2 cyclic nucleotide phosphodiesterase. Clinical studies have shown that ZSP1601 is well-tolerated and safe in both healthy volunteers and patients with NAFLD/NASH, demonstrating improvements in liver chemistries, liver fat content, and fibrosis. The drug has been evaluated in multiple phase 1 and phase 2 clinical trials involving oral administration. Common adverse events include mild to moderate headache and diarrhea[1][3][4][9].